Moderna (MRNA) Stock Forecast & Price Target

$53.09

+0.29 (+0.55%)

(As of 10/25/2024 ET)

Moderna - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 20 Analyst Ratings

Sell
2

Hold
14

Buy
4

Based on 20 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 14 have given a hold rating, and 4 have given a buy rating for MRNA.

Consensus Price Target

$94.65
78.28% Upside

According to the 20 analysts' twelve-month price targets for Moderna, the average price target is $94.65. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $48.00. The average price target represents a forecasted upside of 78.28% from the current price of $53.09.

Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

MRNA Analyst Ratings Over Time

Type	Current Forecast 10/26/23 to 10/25/24	1 Month Ago 9/26/23 to 9/25/24	3 Months Ago 7/28/23 to 7/27/24	1 Year Ago 10/26/22 to 10/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	14 Hold rating(s)	14 Hold rating(s)	14 Hold rating(s)	14 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$94.65	$94.65	$94.65	$94.65
Forecasted Upside	78.28% Upside	78.28% Upside	78.28% Upside	78.28% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Buy these “two-bagger” stocks (Ad)

We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.

Download your free report today!

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Medical Companies	S&P 500
Consensus Rating Score	2.10	2.79	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	79.26% Upside	11,399.35% Upside	8.55% Upside
News Sentiment Rating	Neutral News See Recent MRNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/24/2024	UBS Group 4 of 5 stars		Lower Target	Buy ➝ Buy	$140.00 ➝ $108.00	+104.55%
10/17/2024	Sanford C. Bernstein 3 of 5 stars	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$55.00	-4.28%
10/15/2024	Jefferies Financial Group 2 of 5 stars		Lower Target	Hold ➝ Hold	$65.00 ➝ $55.00	-4.75%
9/19/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$75.00 ➝ $75.00	+6.47%
9/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underperform ➝ Underperform	$60.00 ➝ $48.00	-34.09%
9/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$178.00 ➝ $139.00	+101.19%
Get the Latest News and Ratings for MRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.
9/16/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$155.00 ➝ $125.00	+80.06%
9/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$130.00 ➝ $110.00	+62.87%
9/13/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$70.00 ➝ $60.00	-9.92%
9/13/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
9/13/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$157.00 ➝ $115.00	+65.04%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$88.00 ➝ $70.00	+0.46%
9/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
8/28/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/28/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$82.00	+3.82%
8/7/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold	$85.00 ➝ $80.00	-2.79%
6/27/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
6/27/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	In-Line ➝ In-Line	$120.00 ➝ $120.00	-2.00%
5/3/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$91.00 ➝ $106.00	-15.20%
9/13/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$160.00 ➝ $140.00	+26.96%
8/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $123.00	+13.37%
6/26/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/25/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
2/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	-36.98%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$130.00 ➝ $150.00	-23.76%
1/18/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Livshits Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral	$191.00 ➝ $208.00	+4.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 08:21 PM ET.

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 20, 2024. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

Here are some ways that investors could benefit from investing in Moderna, Inc.:

Moderna's stock price has shown resilience despite recent market fluctuations, indicating strong investor confidence.
Recent analyst reports have highlighted Moderna as a potential buy opportunity, with price targets suggesting room for growth.
Moderna's innovative mRNA technology has positioned the company as a leader in the development of cutting-edge vaccines and therapeutics.
Insider selling of shares by company executives may not necessarily indicate negative sentiment, as it could be part of a pre-planned strategy or profit-taking.
Moderna's consistent focus on research and development, especially in the field of mRNA-based treatments, offers long-term growth potential.

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

Moderna's stock has experienced volatility, which may pose risks for short-term investors seeking stable returns.
The company's high debt-to-equity ratio could indicate financial leverage concerns, impacting its ability to weather economic downturns.
Recent insider selling activities, especially by key executives, may raise questions about the company's future performance and growth prospects.
Analysts have issued mixed ratings on Moderna, with some suggesting caution due to uncertainties in the biotech industry and regulatory challenges.
Market competition and potential disruptions in the healthcare sector could impact Moderna's market share and revenue growth in the future.

MRNA Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $94.65, with a high forecast of $179.00 and a low forecast of $48.00.
: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 14 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
: According to analysts, Moderna's stock has a predicted upside of 78.28% based on their 12-month stock forecasts.
: Over the previous 90 days, Moderna's stock had 4 downgrades and 3 upgrades by analysts.
: Moderna has been rated by research analysts at Bank of America, Barclays, Deutsche Bank Aktiengesellschaft, Hsbc Global Res, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

This page (NASDAQ:MRNA) was last updated on 10/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Stock Forecast & Price Target